<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-148937" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Colestipol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hameed</surname>
            <given-names>Mohammed Hamzah</given-names>
          </name>
          <aff>Medical University of Warsaw</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farzam</surname>
            <given-names>Khashayar</given-names>
          </name>
          <aff>McMaster University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammed Hamzah Hameed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-148937.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Colestipol is an antihyperlipidemic drug approved by the United States Food and Drug Administration (FDA)&#x000a0;as an adjunctive therapy to lower elevated low-density lipoprotein cholesterol in patients with primary hypercholesterolemia unresponsive to dietary modifications alone. The drug can be used as monotherapy or in conjunction with a statin, niacin, or ezetimibe. Colestipol is a cholesterol-lowering drug that reduces the risk of coronary artery disease. This drug belongs to the class of bile acid sequestrants and is one of the earliest drugs used for this purpose.&#x000a0;However,&#x000a0;the current predominant application involves&#x000a0;providing supplementary therapy, especially in cases where statins or alternative lipid-lowering agents prove inadequate in sufficiently reducing cholesterol levels.&#x000a0;</p>
        <p>The drug is adjunctive to dietary modifications and exercise. In addition,&#x000a0;colestipol is used off-label to treat cholestatic pruritus and irritable bowel syndrome.&#x000a0;This activity emphasizes the indications, mechanism of action, adverse event profile, administration, pharmacokinetics, and monitoring strategies for colestipol. This activity&#x000a0;provides healthcare professionals with a scientific foundation for effectively treating primary hypercholesterolemia and related conditions. In addition, this activity&#x000a0;assists healthcare providers in decision-making regarding colestipol prescription and optimizing dosage regimens to minimize adverse reactions, thereby promoting desired patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with primary hypercholesterolemia who may benefit from adjunctive therapy with colestipol based on their lipid profile and responsiveness to dietary modifications alone.</p></list-item><list-item><p>Screen for potential contraindications and assess the suitability of colestipol for patients with cholestatic pruritus and irritable bowel syndrome, recognizing its off-label applications.</p></list-item><list-item><p>Assess patient responses to colestipol therapy by regularly monitoring lipid profiles and adjusting dosage regimens as needed to achieve target cholesterol levels.</p></list-item><list-item><p>Coordinate efforts within the interprofessional team to address knowledge gaps and facilitate ongoing colestipol education, contributing to a comprehensive and informed approach to hypercholesterolemia management.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148937&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148937">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-148937.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Colestipol is an antihyperlipidemic drug approved by the United States Food and Drug Administration (FDA)&#x000a0;as an adjunctive therapy to lower elevated low-density lipoprotein cholesterol in patients with primary hypercholesterolemia unresponsive to dietary modifications alone. The drug can be&#x000a0;used&#x000a0;as monotherapy or in conjunction with a statin, niacin, or ezetimibe.&#x000a0;The drug is adjunctive to dietary modifications and exercise.</p>
        <p>Colestipol belongs to the class of bile acid sequestrants and is used for various indications. This drug was approved for usage in the United States back in 1977 and&#x000a0;is one of the earliest cholesterol-lowering drugs that reduces the risk of coronary artery disease.&#x000a0;However,&#x000a0;the current predominant application involves&#x000a0;providing supplementary therapy, especially in cases where statins or alternative lipid-lowering agents prove inadequate in sufficiently reducing cholesterol levels.<xref ref-type="bibr" rid="article-148937.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Colestipol&#x000a0;is FDA-approved as adjunctive therapy to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia who do not respond to diet modifications only.&#x000a0;The drug&#x000a0;is used as monotherapy or in combination with a statin, niacin, or ezetimibe. Doses of 4 to 16&#x000a0;g/d day are associated with a 12% to 24% reduction in LDL cholesterol, respectively.<xref ref-type="bibr" rid="article-148937.r2">[2]</xref><xref ref-type="bibr" rid="article-148937.r3">[3]</xref>&#x000a0;Higher doses may be associated with increased gastrointestinal adverse effects.<xref ref-type="bibr" rid="article-148937.r4">[4]</xref>&#x000a0;</p>
        <p>Combination therapy with simvastatin is associated with a 52% reduction of LDL cholesterol.<xref ref-type="bibr" rid="article-148937.r2">[2]</xref>&#x000a0;Dual treatment with niacin demonstrated a 43% reduction in LDL cholesterol levels and reduced angiographic progression of coronary artery atherosclerotic lesions by 16.2% compared to 2.4% in individuals receiving a placebo.<xref ref-type="bibr" rid="article-148937.r5">[5]</xref> The&#x000a0;National Lipid Association (NLA) guidelines endorse bile acid sequestrants like colestipol for hypercholesteremia.<xref ref-type="bibr" rid="article-148937.r6">[6]</xref>&#x000a0;According to the NLA guidelines, hypercholesterolemia during pregnancy and breastfeeding, particularly in patients with familial hypercholesterolemia, may be treated with bile acid sequestrants.<xref ref-type="bibr" rid="article-148937.r7">[7]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Colestipol may be used in the treatment of heterozygous familial hypercholesterolemia. Although colestipol is effective, it is poorly tolerated due to gastrointestinal adverse effects.<xref ref-type="bibr" rid="article-148937.r8">[8]</xref>&#x000a0;Colestipol may be used in combination with a statin.<xref ref-type="bibr" rid="article-148937.r4">[4]</xref>&#x000a0;A trial in children with familial hypercholesterolemia treated with colestipol found a 19.5% reduction in LDL-C levels after&#x000a0;8 weeks of therapy.<xref ref-type="bibr" rid="article-148937.r9">[9]</xref></p>
        <p>Colestipol is&#x000a0;used&#x000a0;off-label to treat cholestatic pruritus and irritable bowel syndrome.&#x000a0;Pruritus associated with cholestasis, particularly in primary sclerosing cholangitis, may be treated with colestipol.<xref ref-type="bibr" rid="article-148937.r10">[10]</xref>&#x000a0;Colestipol may be better tolerated compared to therapy with cholestyramine.<xref ref-type="bibr" rid="article-148937.r11">[11]</xref>&#x000a0;The American Association for the Study of Liver Diseases endorses bile acid sequestrants such as colestipol for cholestatic pruritus in primary biliary cholangitis. These agents are positively charged resins that work by binding to negatively charged anions, including bile acids. Although clinical trials proving efficacy are limited, they have a long track record of clinical use. Patients may prefer colestipol and colesevelam, which are available in tablet forms.<xref ref-type="bibr" rid="article-148937.r12">[12]</xref></p>
        <p>A prospective, controlled trial with 92 patients performed by Hagag et al demonstrated the effectiveness of colestipol as an adjunct therapy to methimazole for treating hyperthyroidism.<xref ref-type="bibr" rid="article-148937.r13">[13]</xref> Greater efficacy was seen in&#x000a0;severe cases of thyrotoxicosis.<xref ref-type="bibr" rid="article-148937.r13">[13]</xref></p>
        <p>In a study of 141 patients evaluating the role of bile acids in the pathogenesis of irritable bowel syndrome (IBS),&#x000a0;treatment with colestipol improved IBS symptoms (IBS severity scoring system 220 &#x000b1; 109 vs 277&#x000a0;&#x000b1; 106).<xref ref-type="bibr" rid="article-148937.r14">[14]</xref>&#x000a0;As such, colestipol may be used to treat bile acid diarrhea. However,&#x000a0;colestipol is often discontinued due to poor tolerability.<xref ref-type="bibr" rid="article-148937.r15">[15]</xref></p>
        <p>Colestipol&#x000a0;is successfully used to treat digoxin toxicity. Colestipol interrupts the enterohepatic circulation of digoxin and increases fecal excretion. One case report by Payne et al reported a reduced half-life of 55 hours compared to a predicted half-life of 85.<xref ref-type="bibr" rid="article-148937.r16">[16]</xref></p>
        <p>The clinical trial evaluated colestipol's viability as an oral phosphate binder in hemodialysis patients and reported positive outcomes. The findings suggest the potential for a larger-scale trial to ascertain colestipol's effectiveness as a phosphate binder.<xref ref-type="bibr" rid="article-148937.r17">[17]</xref></p>
      </sec>
      <sec id="article-148937.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Colestipol is a large basic anion-exchange resin copolymer&#x000a0;that&#x000a0;is nonabsorbable and insoluble in water.<xref ref-type="bibr" rid="article-148937.r18">[18]</xref>&#x000a0;The primary mechanism of action is the formation of insoluble complexes with bile acids in the small intestine that are subsequently excreted in the feces. Bile acids emulsify and solubilize lipids in the intestinal lumen as part of normal digestion. The rate-limiting&#x000a0;step&#x000a0;in bile acid synthesis involves hydroxylation of the steroid nucleus of cholesterol by cholesterol 7-alpha-hydroxylase.<xref ref-type="bibr" rid="article-148937.r19">[19]</xref>&#x000a0;Data show that 95% of bile acids are recycled via enterohepatic circulation to the liver, while 5% are excreted in the feces.<xref ref-type="bibr" rid="article-148937.r19">[19]</xref></p>
        <p>Increased fecal excretion of bile acids reduces the total bile acid pool available for enterohepatic circulation. As a result, upregulation of cholesterol 7-alpha-hydroxylase leads to increased conversion of cholesterol into bile acids, reducing total serum cholesterol levels. Further upregulation of hepatic low-density lipoprotein receptors (LDLR) to replenish intrahepatic cholesterol stores available for bile acid synthesis leads to increased uptake of LDL-C and an overall reduction in plasma LDL cholesterol (LDL-C) levels.</p>
        <p>In cases of&#x000a0;thyrotoxicosis, enterohepatic circulation of thyroid hormones, including thyroxine (T4) and triiodothyronine (T3), increases.<xref ref-type="bibr" rid="article-148937.r13">[13]</xref>&#x000a0;Interaction between positively charged nitrogen atoms of colestipol with negatively charged iodothyronines leads to increased fecal excretion of iodothyronines.<xref ref-type="bibr" rid="article-148937.r13">[13]</xref></p>
        <p>According to a systematic review, colestipol is suggested for moderate to severe cholestatic pruritus. The mechanism of colestipol in cholestatic pruritus is by binding to bile acids within the small intestine, preventing reabsorption and facilitating elimination via feces.<xref ref-type="bibr" rid="article-148937.r20">[20]</xref></p>
        <p>
<bold>Pharmacokinetics&#x000a0;</bold>
</p>
        <p><bold>Absorption:</bold> Colestipol demonstrates negligible solubility in water despite&#x000a0;its hydrophilic nature and is not hydrolyzed by digestive enzymes.&#x000a0;The high molecular weight polymer present in colestipol appears to render it nonabsorbable.&#x000a0;The primary effects of bile acid sequestrants like colestipol are restricted to the intestine.<xref ref-type="bibr" rid="article-148937.r21">[21]</xref></p>
        <p><bold>Distribution:</bold> In humans, less than 0.17% of a single dose labeled with ^14C-colestipol is excreted in the urine after 60 days of consistent administration at 20&#x000a0;g daily. This low percentage suggests minimal systemic distribution or absorption of colestipol hydrochloride within the body.</p>
        <p><bold>Metabolism:</bold> The binding of bile acids to colestipol creates an insoluble compound that cannot be reabsorbed and is excreted in the feces.</p>
        <p><bold>Elimination:</bold> Bile acids ordinarily undergo extensive (&#x0003e;95%) enterohepatic recirculation, are secreted in bile, act as fat-solubilizing compounds in the upper intestine, and are reabsorbed in the distal small bowel. However, colestipol disrupts this cycle, resulting in the excretion of colestipol-bound bile acids in the feces.<xref ref-type="bibr" rid="article-148937.r1">[1]</xref>&#x000a0;Colestipol is minimally excreted in the urine&#x000a0;and predominantly in feces&#x000a0;due to&#x000a0;its nonabsorbable nature.</p>
      </sec>
      <sec id="article-148937.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Colestipol is available to patients in&#x000a0;2 forms&#x02014;oral tablet or granular form as a powdered suspension. The powdered suspension is also available in a flavored form to improve palatability. However, the flavored suspension&#x000a0;is taken cautiously in patients with phenylketonuria, as it contains phenylalanine.</p>
        <p>Colestipol is available in various&#x000a0;formulations and doses, including granules in a bottle containing 5 g of the medication and flavored granules in packets, each containing 5 g of the substance. Furthermore, the oral form is available in tablets with a dosage of 1 g per tablet.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Patients with phenylketonuria must consult their clinician before initiating therapy with a flavored colestipol suspension. Powdered suspensions of colestipol should be mixed with water or other fluids before ingestion to prevent inhalation or esophageal distress. Other medications, such as fat-soluble vitamins, should be&#x000a0;ingested 1 hour before or 4 hours after the administration of colestipol.<xref ref-type="bibr" rid="article-148937.r22">[22]</xref></p>
        <p>Colestipol tablets are recommended in 2 to 16&#x000a0;g daily. Therapy should be initiated at a dosage of 2&#x000a0;g/d. Colestipol powdered suspension is recommended in a dosage&#x000a0;of&#x000a0;1 to&#x000a0;6 packets per day. One packet contains 5&#x000a0;g of colestipol.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment</bold>:&#x000a0;There is no dosage adjustment information for hepatic impairment for colestipol in the product labeling.</p>
        <p><bold>Renal impairment</bold>:&#x000a0;There is no dosage adjustment information for renal impairment for colestipol in the product labeling.</p>
        <p><bold>Pregnancy considerations</bold>: Colestipol is safe since it is not systemically absorbed. However, colestipol may induce the malabsorption of fat-soluble vitamins (A, D, E, and K), which&#x000a0;is hazardous to the mother and child. Therefore, the benefits of drug therapy should be weighed against the risks before the initiation of treatment.<xref ref-type="bibr" rid="article-148937.r23">[23]</xref></p>
        <p>As per the NLA guidelines, most women diagnosed with hypercholesterolemia are advised against drug therapy during pregnancy. However, those with atherosclerotic cardiovascular disease or homozygous familial hypercholesterolemia may require pharmacotherapy. Bile acid sequestrants are considered reasonable therapeutic options during pregnancy.<xref ref-type="bibr" rid="article-148937.r7">[7]</xref></p>
        <p><bold>Breastfeeding considerations</bold>:&#x000a0;Colestipol, a nonabsorbable resin, does not&#x000a0;reach the maternal bloodstream and consequently does not transfer to the infant through breast milk. Accordingly, colestipol is considered safe during lactation.<xref ref-type="bibr" rid="article-148937.r24">[24]</xref></p>
        <p><bold>Pediatric patients</bold>: The adverse event profile of colestipol in patients under 18 has not been established. However, colestipol has been used safely&#x000a0;in pediatric patients with familial hypercholesterolemia.<xref ref-type="bibr" rid="article-148937.r4">[4]</xref>&#x000a0;According to the&#x000a0;NLA&#x000a0;guidelines, statins and bile acid sequestrants can be considered for children and adolescents.<xref ref-type="bibr" rid="article-148937.r6">[6]</xref></p>
        <p><bold>Older patients</bold>: The gastrointestinal adverse effects of colestipol, such as constipation, may be more pronounced in patients over the age of 60.<xref ref-type="bibr" rid="article-148937.r25">[25]</xref></p>
      </sec>
      <sec id="article-148937.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse&#x000a0;Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Most adverse effects caused by colestipol therapy are&#x000a0;related to the gastrointestinal system. Colestipol can cause a wide range of adverse effects, including constipation, bloating, dyspepsia, and nausea.<xref ref-type="bibr" rid="article-148937.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Constipation is the most common&#x000a0;adverse drug reaction&#x000a0;and ranges in severity from mild cases to severe cases.&#x000a0;The reaction is often a cause of poor compliance and discontinuation of therapy.<xref ref-type="bibr" rid="article-148937.r27">[27]</xref>&#x000a0;Patients aged 65 or older and patients using a larger dose of colestipol are more prone to constipation.<xref ref-type="bibr" rid="article-148937.r25">[25]</xref>&#x000a0;Constipation may be alleviated with increased fluid and fiber intake, as well as the use of stool softeners. Colestipol may aggravate preexisting hemorrhoids.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The usage of colestipol in powdered suspension form may cause decreased palatability. Flavored suspensions of colestipol are used to improve palatability.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Non-gastrointestinal&#x000a0;adverse effects are infrequently reported. These include infrequent occurrences of cardiovascular symptoms such as angina, musculoskeletal symptoms such as joint pains and arthritis, and neurologic symptoms such as migraine headaches.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol may cause transient elevations in alkaline phosphatase levels, although the clinical significance is unknown.<xref ref-type="bibr" rid="article-148937.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol therapy&#x000a0;is reported to cause asymptomatic hepatotoxicity with elevated serum transaminases. However, the mechanism by which colestipol causes hepatotoxicity is unknown.<xref ref-type="bibr" rid="article-148937.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol may cause hyperchloremic metabolic acidosis.</p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol may induce malabsorption of fat-soluble vitamins (vitamins A, D, E, and K). Patients with preexisting deficiencies of these vitamins should consult their clinician before commencing therapy with colestipol. These vitamins should be taken 4 hours after colestipol.<xref ref-type="bibr" rid="article-148937.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol can reduce the absorption of beta blockers, fibrates, and ezetimibe.<xref ref-type="bibr" rid="article-148937.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol may reduce the absorption of many drugs if they are given concomitantly with colestipol. Anionic drugs such as warfarin, thiazide diuretics, propanolol, levothyroxine, and digitalis should be given 1 hour before or 4 hours after colestipol.<xref ref-type="bibr" rid="article-148937.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-148937.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Colestipol should not be used in patients with known hypersensitivity to the drug or its components.</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol should be avoided for use in patients with disorders that cause decreased intestinal motility, in patients with a recent history of abdominal surgery, and patients with a history of recent episodes of intestinal obstruction.<xref ref-type="bibr" rid="article-148937.r22">[22]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol is contraindicated in patients undergoing therapy with mycophenolic acid. As colestipol binds to bile acids, it reduces the absorption of mycophenolic acid and may reduce&#x000a0;the efficacy.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol causes elevated triglyceride levels. Lyons et al demonstrated an 8.9% rise in triglyceride levels in patients treated with colestipol.<xref ref-type="bibr" rid="article-148937.r28">[28]</xref>&#x000a0;Colestipol should be avoided in patients with triglyceride levels above 400 mg/dL. It may be used in patients with serum levels below&#x000a0;200 mg/dL of triglyceride.<xref ref-type="bibr" rid="article-148937.r22">[22]</xref>&#x000a0;Therefore, as a precaution, clinicians should reserve this drug for use in patients with hypercholesterolemia without associated hypertriglyceridemia.<xref ref-type="bibr" rid="article-148937.r18">[18]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol is a bile acid sequestrant.&#x000a0;As a large anion exchange resin, it may bind numerous intestine molecules. Of note, colestipol may bind to free triiodothyronine (T3), resulting in increased fecal excretion of T3 and reduced enterohepatic circulation.<xref ref-type="bibr" rid="article-148937.r29">[29]</xref>&#x000a0;As a result, colestipol therapy may worsen symptoms in patients with preexisting hypothyroidism. Therefore, patients on colestipol therapy should consider consulting their clinician before commencing treatment.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colestipol should be avoided in patients with complete biliary obstruction.<xref ref-type="bibr" rid="article-148937.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic use of colestipol may cause an increased risk of bleeding due to hypoprothrombinemia resulting from vitamin K deficiency. However, this condition can be promptly treated with parenteral vitamin K1 and prevented from recurring by administering oral vitamin K1.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-148937.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Periodic monitoring of serum lipoproteins is recommended in patients taking colestipol to&#x000a0;assess treatment response and dosage modifications.&#x000a0;As colestipol is known to cause constipation of varying severity and may cause intestinal obstruction, monitoring of constipation at 4- to 6-week intervals is recommended. Worsening constipation or failure to meet therapeutic goals may require combination therapy or replacement with alternate therapy.&#x000a0;</p>
        <p>Clinicians should regularly monitor patients with preexisting fat-soluble vitamin deficiencies (A, D, E, and K)&#x000a0;when on colestipol therapy. Colestipol may impede the absorption of fat-soluble vitamins by acting as a bile acid sequestrant.<xref ref-type="bibr" rid="article-148937.r30">[30]</xref>&#x000a0;If any of these vitamins are deficient, signs should be recognized, and treatment should be promptly started.&#x000a0;As colestipol may cause hyperchloremic metabolic acidosis, signs of hyperchloremic acidosis may ensue. These include headaches, seizures, increased respiratory rate, and arrhythmias.&#x000a0;Patients on warfarin therapy should have their International Normalized Ratio (INR) monitored regularly as the absorption is affected by colestipol.<xref ref-type="bibr" rid="article-148937.r21">[21]</xref></p>
      </sec>
      <sec id="article-148937.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>No reports of toxicity associated with colestipol therapy have been reported other than the adverse events described above. Colestipol is relatively safe as it is not absorbed systemically and does not cause severe adverse effects. In the event of an overdose, the primary concern&#x000a0;is the potential obstruction of the gastrointestinal tract.&#x000a0;</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Treatment decisions in overdose&#x000a0;are influenced by the location and severity of any potential obstruction, along with the assessment of normal gut motility.</p>
        <p>
<bold>Recommendations</bold>
</p>
        <p>Patients often report poor tolerability to colestipol due to&#x000a0;the many gastrointestinal adverse effects and poor&#x000a0;palatability.<xref ref-type="bibr" rid="article-148937.r31">[31]</xref> Therefore, healthcare&#x000a0;professionals&#x000a0;should consider this and modify treatment by offering a different drug formulation.</p>
      </sec>
      <sec id="article-148937.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Colestipol is a bile acid sequestrant that may be offered to patients to treat various conditions, such as hypercholesterolemia or pruritus associated with chronic liver disease. Colestipol&#x000a0;is&#x000a0;less commonly prescribed in the current age due to poor compliance with use and poor tolerability. Still, colestipol is highly effective in managing hypercholesterolemia and pruritus. Therefore, healthcare professionals treating these conditions should be familiar with&#x000a0;the properties. This familiarity may enable them to offer patients an improved quality of life.</p>
        <p>Clinicians initiating colestipol for hypercholesterolemia&#x000a0;should review and consider atherosclerotic cardiovascular disease&#x000a0;risk factors.&#x000a0;As per the NLA, it is advisable to consult or refer children with familial hypercholesterolemia to a lipid specialist.<xref ref-type="bibr" rid="article-148937.r32">[32]</xref>&#x000a0;Nurses should be aware of colestipol's most commonly encountered adverse effects to develop strategies to monitor their occurrence and report them to clinicians. The pharmacist should serve as the main point of contact for those members of the interprofessional team seeking advice on the dosage and administration of colestipol, checking for drug interactions, risk mitigation of adverse effects, and giving clear instructions to patients on how to use the drug.&#x000a0;</p>
        <p>A study investigated the effectiveness of the multidisciplinary lipid clinic in enhancing guideline-based care for lipid disorders within the healthcare system.&#x000a0;Though a modest referral rate from active cardiology and primary care providers, the clinic attended to 83 patients, significantly improving the diagnosis and management of conditions such as familial hypercholesterolemia and dyslipidemia. The impact included increased use of evidence-based therapies, decreased lipid levels, and adaptive measures like transitioning to telehealth for sustained capacity. These results underscore the potential of the multidisciplinary lipid clinic to enhance patient outcomes.<xref ref-type="bibr" rid="article-148937.r33">[33]</xref>&#x000a0;Coordination between all interprofessional healthcare team members, including clinicians, specialists, pharmacists, and nurses, is crucial in enhancing outcomes associated with colestipol therapy.</p>
      </sec>
      <sec id="article-148937.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148937&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148937">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/148937/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=148937">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-148937.s11">
        <title>References</title>
        <ref id="article-148937.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <chapter-title>Colestipol</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>9</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">31643751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Packard</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Caslake</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Colquhoun</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lorimer</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>236</fpage>
            <page-range>236-49</page-range>
            <pub-id pub-id-type="pmid">8620338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Insull</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Demke</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Dujovne</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Eckert</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hodis</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients.</article-title>
            <source>Atherosclerosis</source>
            <year>1995</year>
            <month>Jan</month>
            <day>20</day>
            <volume>112</volume>
            <issue>2</issue>
            <fpage>223</fpage>
            <page-range>223-35</page-range>
            <pub-id pub-id-type="pmid">7772081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCrindle</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Helden</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cullen-Dean</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Conner</surname>
                <given-names>WT</given-names>
              </name>
            </person-group>
            <article-title>A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia.</article-title>
            <source>Pediatr Res</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>715</fpage>
            <page-range>715-21</page-range>
            <pub-id pub-id-type="pmid">12032266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blankenhorn</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Nessim</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Sanmarco</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Azen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Cashin-Hemphill</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.</article-title>
            <source>JAMA</source>
            <year>1987</year>
            <month>Jun</month>
            <day>19</day>
            <volume>257</volume>
            <issue>23</issue>
            <fpage>3233</fpage>
            <page-range>3233-40</page-range>
            <pub-id pub-id-type="pmid">3295315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Bays</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>McKenney</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wild</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>WV</given-names>
              </name>
            </person-group>
            <article-title>National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.</article-title>
            <source>J Clin Lipidol</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-69</page-range>
            <pub-id pub-id-type="pmid">25911072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Kris-Etherton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sikand</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>La Forge</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Wild</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Daviglus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferdinand</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Vijayaraghavan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Deedwania</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Aberg</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>McKenney</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Bays</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Underberg</surname>
                <given-names>JA</given-names>
              </name>
              <collab>NLA Expert Panel</collab>
            </person-group>
            <article-title>National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.</article-title>
            <source>J Clin Lipidol</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>9</volume>
            <issue>6 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-122.e1</page-range>
            <pub-id pub-id-type="pmid">26699442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vuorio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuoppala</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kovanen</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Humphries</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Tonstad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wiegman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drogari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ramaswami</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Statins for children with familial hypercholesterolemia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Nov</month>
            <day>07</day>
            <volume>2019</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">31696945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Lozano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Henrikson</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blasi</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Whitlock</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <source>Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]</source>
            <publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name>
            <publisher-loc>Rockville (MD)</publisher-loc>
            <year>2016</year>
            <month>08</month>
            <pub-id pub-id-type="pmid">27559556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scaldaferri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pizzoferrato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ponziani</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Use and indications of cholestyramine and bile acid sequestrants.</article-title>
            <source>Intern Emerg Med</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>205</fpage>
            <page-range>205-10</page-range>
            <pub-id pub-id-type="pmid">21739227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bunchorntavakul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Pruritus in chronic cholestatic liver disease.</article-title>
            <source>Clin Liver Dis</source>
            <year>2012</year>
            <month>May</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>331</fpage>
            <page-range>331-46</page-range>
            <pub-id pub-id-type="pmid">22541702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.</article-title>
            <source>Hepatology</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>394</fpage>
            <page-range>394-419</page-range>
            <pub-id pub-id-type="pmid">30070375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagag</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nissenbaum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Role of colestipol in the treatment of hyperthyroidism.</article-title>
            <source>J Endocrinol Invest</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>725</fpage>
            <page-range>725-31</page-range>
            <pub-id pub-id-type="pmid">9972670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bajor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>T&#x000f6;rnblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rudling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ung</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Simr&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.</article-title>
            <source>Gut</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-92</page-range>
            <pub-id pub-id-type="pmid">24727487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrugia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arasaradnam</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bile acid diarrhoea: pathophysiology, diagnosis and management.</article-title>
            <source>Frontline Gastroenterol</source>
            <year>2021</year>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>500</fpage>
            <page-range>500-507</page-range>
            <pub-id pub-id-type="pmid">34712468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Payne</surname>
                <given-names>VW</given-names>
              </name>
              <name>
                <surname>Secter</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Noback</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Use of colestipol in a patient with digoxin intoxication.</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1981</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>902</fpage>
            <page-range>902-3</page-range>
            <pub-id pub-id-type="pmid">7297421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hood</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wolley</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Kendrik-Jones</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients.</article-title>
            <source>Nephrology (Carlton)</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>250</fpage>
            <page-range>250-6</page-range>
            <pub-id pub-id-type="pmid">25557531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heel</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Pakes</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Speight</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia.</article-title>
            <source>Drugs</source>
            <year>1980</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-80</page-range>
            <pub-id pub-id-type="pmid">6988203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGlone</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Bloom</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Bile acids and the metabolic syndrome.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2019</year>
            <month>May</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>326</fpage>
            <page-range>326-337</page-range>
            <pub-id pub-id-type="pmid">30453753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebhohon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Systematic review: efficacy of therapies for cholestatic pruritus.</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2023</year>
            <volume>16</volume>
            <fpage>17562848231172829</fpage>
            <pub-id pub-id-type="pmid">37255856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <chapter-title>Cholesterol Lowering Drugs</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2021</year>
            <month>3</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">27809434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Armani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKenney</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Safety considerations with gastrointestinally active lipid-lowering drugs.</article-title>
            <source>Am J Cardiol</source>
            <year>2007</year>
            <month>Mar</month>
            <day>19</day>
            <volume>99</volume>
            <issue>6A</issue>
            <fpage>47C</fpage>
            <page-range>47C-55C</page-range>
            <pub-id pub-id-type="pmid">17368279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halpern</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Pinnelas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mehta-Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Economy</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Use of Medication for Cardiovascular&#x000a0;Disease&#x000a0;During Pregnancy: JACC State-of-the-Art Review.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>05</day>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>457</fpage>
            <page-range>457-476</page-range>
            <pub-id pub-id-type="pmid">30704579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <chapter-title>Colestipol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">30000452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steinmetz</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Colesevelam hydrochloride.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2002</year>
            <month>May</month>
            <day>15</day>
            <volume>59</volume>
            <issue>10</issue>
            <fpage>932</fpage>
            <page-range>932-9</page-range>
            <pub-id pub-id-type="pmid">12040732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Crowder</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Frankel</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Lam-Himlin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Singhi</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Stanich</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Colesevelam and colestipol: novel medication resins in the gastrointestinal tract.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>1530</fpage>
            <page-range>1530-7</page-range>
            <pub-id pub-id-type="pmid">24921636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Gleeson</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Osborne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Messham</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kurien</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcomes in patients diagnosed with bile-acid diarrhoea.</article-title>
            <source>Eur J Gastroenterol Hepatol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>240</fpage>
            <page-range>240-5</page-range>
            <pub-id pub-id-type="pmid">26636406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sirmans</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Banh</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Colestipol-induced hepatotoxicity.</article-title>
            <source>Pharmacotherapy</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>513</fpage>
            <page-range>513-6</page-range>
            <pub-id pub-id-type="pmid">11310528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witztum</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Schonfeld</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Thyroid hormone and thyrotropin levels in patients placed on colestipol hydrochloride.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1978</year>
            <month>May</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>838</fpage>
            <page-range>838-40</page-range>
            <pub-id pub-id-type="pmid">262768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwarz</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Witztum</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Schonfeld</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol.</article-title>
            <source>Pediatrics</source>
            <year>1980</year>
            <month>Feb</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>243</fpage>
            <page-range>243-50</page-range>
            <pub-id pub-id-type="pmid">7354970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bile Acid diarrhea: prevalence, pathogenesis, and therapy.</article-title>
            <source>Gut Liver</source>
            <year>2015</year>
            <month>May</month>
            <day>23</day>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>332</fpage>
            <page-range>332-9</page-range>
            <pub-id pub-id-type="pmid">25918262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldberg</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Rader</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Cromwell</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ziajka</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.</article-title>
            <source>J Clin Lipidol</source>
            <year>2011</year>
            <season>May-Jun</season>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>133</fpage>
            <page-range>133-140</page-range>
            <pub-id pub-id-type="pmid">21600517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148937.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>McMinn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lesko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sturm</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brownson</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Rahm</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis.</article-title>
            <source>Implement Sci Commun</source>
            <year>2021</year>
            <month>Mar</month>
            <day>19</day>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">33741054</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
